Mouse model and cell lines. The Trp53 fl/fl ; Rb1 fl/fl ; Pten fl/fl ; Rosa26 LSL-Luciferase/LSL-Luciferase (PRP-L/L) mouse model of SCLC has been described previously (1). Rosa26 LSL-tdTomato/LSL-tdTomato mice were obtained from Jackson Laboratories (Gt(ROSA)26Sor tm14(CAG-tdTomato)Hze ) and crossed into the PRP-L/L model to obtain Trp53 fl/fl ; Rb1 fl/fl ; Pten fl/fl ; Rosa26 LSL-tdTomato/LSL-Luciferase mice. Tumors were initiated by intratracheal delivery of 2×10 8 plaqueforming units (p.f.u.) of adenovirus expressing Cre recombinase under the control of a CGRP promoter (Ad5-CGRP-Cre (2)), as previously described (3). Adenoviral stocks were purchased from the Viral Vector Core Facility at the University of Iowa Carver College of Medicine. Candidates for arteriovenous shunt surgery were identified by in vivo bioluminescence imaging using the IVIS Spectrum In Vivo Imaging System (PerkinElmer). Murine SCLC cell lines (AF1281-M1, AF3291LN) were generated from mSCLC tumors isolated from Trp53 fl/fl ; Rb1 fl/fl ; Rosa26 LSL-tdTomato/+ or Trp53 fl/fl ; Rb1 fl/fl ; Pten fl/fl ; Rosa26 LSL-tdTomato/LSL-Luciferase mice as previously described (4). Shunt Surgery. All animal-based procedures were approved by the Massachusetts Institute of Technology Committee on Animal Care (CAC), Division of Comparative
return through the carotid artery and jugular vein, respectively, in the conscious mouse ( Fig. 1A) . During the four-day longitudinal studies, the total collected blood volume is monitored. If depleted blood volume exceeds 1% of the animal's body weight (for example 260 µL for a 25g mouse), per MIT DCM guidelines, healthy-mouse donor blood (of same strain and sex) is infused directly into the mouse using the jugular vein catheter, equivalent to the amount removed.
Optical Detection Platform. The optical system is comprised of two optical trains, making up two compact vertical microscopes. The top optical train divides the laser beam (OBIS 532 LS, Coherent Inc) into two separate beams that are focused along one axis to produce two illumination lines projected at the sample focal plane (perpendicular to the blood flow channel) for precise velocity measurements of the flowing CTCs ( Fig. S1A-B) . The laser passes through a line filter and polarizing beam splitters to generate the two beams with minimal losses. Next, the two laser lines pass through a cylindrical lens to focus the two beams into lines. The focused lines are then projected onto the microfluidic channel with a 4F optical system. The dichroic mirror and longpass filters, placed directly above the detection region, pass a filtered fluorescence signal to the PMT (Hamamatsu H10722-20) by blocking the 532 nm laser line signal with a notch filter (532 nm StopLine single-notch filter, Semrock). A 90:10 beam splitter is added before the PMT to allow for imaging of the illumination region for device alignment purposes.
The bottom optical train is similar in configuration to the top train and uses a second green laser to illuminate a circular region covering the valves, enabling fluorescent and bright field imaging for confirming successful CTC sorting and valve functionality throughout the experiment.
Microfluidic Device Design and Fabrication. The microfluidic device for sorting minute amounts of blood containing single CTCs was designed to have one inlet to a 1000μm-long microfluidic channel that bifurcates into two channel outlets (90º apart, Fig. 1B-C) ; one for returning the blood to the mouse and the other for collecting the sorted CTC-containing blood sample. The fabrication was performed using standard soft lithographic techniques on two four-inch wafers. A single layer of photoresist (SU8 2050, Microchem, Newton, MA) was patterned to create the pneumatic channels on the valve control wafer. For the blood flow channel, AZ9260 positive resist (MicroChemicals) was exposed, developed, and then reflowed at 120˚C for 10 minutes to create the half ellipsoid channel profile necessary for a complete valve seal ( Fig. S2) (8) .
A mixture of PDMS (Polydimethylsiloxane) and its curing agent (SYLGARD 184 A/B, Dowcorning, Midland, MI, USA) at a 10:1 ratio was spun on top of the actuation wafer to a thickness of 50 µm and baked in an oven set to 65 ˚C for at least 3 hours. For the flow channel layer, the mixture was poured to a thickness of ~5 mm and cured at 65 ˚C for 3 hours. Afterwards, the flow channel layer was peeled off and punched with a 0.75 mm puncher (Harris Uni-Core, Ted Pella Inc., Reading, CA) to define the inlet and outlets to and from the channel, respectively, and diced to prepare for bonding. The flow channel devices and the actuation layers were then treated with oxygen plasma (100 watt, 1 ccm, 140 torr, 10 sec). Next, the flow layer was aligned to the actuation layer and transferred to a hot plate set to 85 ˚C. After 15 minutes, the assembled PDMS layers were peeled off and punched with a 0.75 mm puncher to define inlets to the actuation channels. The assembled PDMS layers were treated with oxygen plasma (100 watt, 1 ccm, 140 torr, 10 sec) for irreversible bonding to a glass slide (Fisherbrand 1x3", Fisher Scientific, Pittsburgh, PA).
Prior to flow experiments, the device was aligned to project the two laser lines across the flow channel approximately 8 mm away from the valve actuation region. The device was then primed with Heparinized-Saline (diluted to 100 USP units per mL, NDC 25021-400-30) to prevent any clotting within the microfluidic channel.
Real-Time Data Processing and System
Control. The PMT module generates an output voltage that is sampled by a NI USB-6009 (National Instruments) 14 bit analog-to-digital converter. This analog-to-digital converter is also used to output the control voltage signals for the peristaltic pump and the PMT gain. The PMT voltage is acquired and displayed in real time in LabVIEW (National Instruments) at 20,000 samples per second. The raw data is filtered with a low pass filter to remove spurious noise and the output of a running median filter is subtracted to remove low frequency drift or any DC offset. Upon transit of a fluorescent cell or particle, the PMT output signal passes a specific threshold, triggering the NI USB-9472 device to actuate the SMC Solenoid Valves (S070A-6DC, 8 ports) that are connected to an external 6-volt power supply.
During non-sorting operation of the system (i.e. cell counting experiments), the first valve (V1) region is kept sealed to force the blood to flow directly through to the opposite outlet and back into the jugular vein catheter of the mouse (Top-view image, Fig. 1b ). When the sorting functionality is activated, and upon detection of a cell, its velocity is calculated ( Fig. S4A ) and used to estimate the time of its arrival at the valve region of the channel, all using a virtual instrument (VI) program in LabVIEW ( Fig. S4B) . V2 then closes immediately and V1 opens for an amount of time equal to twice the estimated time of arrival of the cell at the valve to deflect a 127±47 nL (or 76±28 nL with a valve actuation delay) blood bolus containing the cell (Fig. S4C) . This amount of blood per single sort provides an upper limit for the number of events we can collect from a mouse over the four-day study. For a 25g mouse, a maximum number of ~2,600 total events can be collected without the need for fluid replacement, per MIT DCM guidelines.
After CTC enrichment with RBC lysis and MACS (described below), the cells were sorted using our secondary single-CTC sorting chip. Upon detection of a single fluorescent CTC in the secondary single-cell sorting chip ( Fig. 1E) , micro-valves actuate to push the cell into the parallel channel. The micro-valves then seal the primary channel and sample flow is stopped to introduce fresh buffer into the parallel channel, releasing the cell out of the chip into the tubing and then into a collection well containing TCL buffer (QIAGEN) with 1% 2-mercaptoethanol for downstream scRNA-seq ( Fig. S6C) .
CTC enrichment by RBC lysis and MACS. Following CTC isolation, the collected blood
sample is first treated with ACK Lysing Buffer (Gibco A10492-01) to remove RBCs, then rinsed, filtered using a 30µm Pre-Separation Filter (Miltenyi Biotec, #130-041-407), and processed through magnetic activated cell sorting (MACS) using mouse CD45 MicroBeads (Miltenyi #130-052-301) and MS columns (Miltenyi #130-042-201) to remove CD45positive cells, according to the manufacturers' protocols. The final product is then diluted to a total volume of 2 mL of MACS buffer and flowed through the secondary single-CTC sorting chip.
Characterization with Cell Line and Beads.
To validate the sensitivity of the system to detect fluorescent cells in blood, 5-peak FACS calibration beads (Sphero PE 5-peak, Spherotech Inc) were spiked into mouse blood and flowed through the device at 30 μL/min ( Fig. S3) . To validate the sorting functionality of the system, a tumor cell line (AF1281-M1) was established from a mouse with autochthonous small cell lung cancer expressing a bright and stable cytoplasmic tdTomato fluorescent protein. Cells were then counted using Coulter Counter (Multisizer 4, Beckman-Coulter) and re-suspended in 500 µL of mouse blood at different densities (10, 100, 500, and 1000 cells, Fig. S4 ).
JQ1 Treatment of Tumor-Bearing Mice.
Tumor-bearing SCLC mice were treated with 10 mg/kg JQ1 (Cayman Chemical) by intravenous injection daily for the duration of the study. JQ1 was dissolved in DMSO to make a 20 mg/mL stock, then diluted 1:10 with 10% beta-cyclodextrin in 0.9% saline to obtain a working concentration of 2 mg/mL. Vehicletreated control mice received an equivalent dose of DMSO diluted 1:10 with 10% betacyclodextrin in 0.9% saline ( Fig. S5 ). mode. For each cell, we enumerated genes for which at least one read was mapped, and the average expression level of a curated list of housekeeping genes. We excluded from analysis profiles with fewer than 500 detected genes or an average housekeeping expression below 0.5 log2(TPM).
Dissociation of Tumor Samples for

Identification of leukocytes and correction of platelet effect. A matrix of TPM estimates
for all genes across all cells resulted from preprocessing of RNA-Seq data. A raw principal component analysis was run for each sample, and the first PC separated cells of immune lineage from cells expressing epithelial genes. We selected from overlaps between this first PC and a curated set of immune-related genes (Table S1) to score CTCs according to their immune score. Cells with an average immune score below 0.5 log2(TPM) were taken forward for analysis of their transcriptomes as CTCs.
Likewise, a curated set of platelet-related genes ( Table S1 ) was used to develop a platelet signature for each CTC transcriptome. The signal of this platelet signature was then regressed out using the RegressOut function in Seurat.
Principal Component Analysis of CTCs. We performed a gene selection based on a binning strategy across expression using Seurat to define a unique set of variable genes for each treated and untreated mouse, as well as combined sets of treated and untreated mice. Generation of Mock Data. To simulate current methods of terminal bleed assays for CTC collection across an acute time scale, we generated a series of mock datasets using our true, continuously collected data. At each time point, the CTCs from a single treated mouse were selected without replacement. This process was exhaustively repeated five times to generate all unique treated mock data over which further differential expression analysis was performed.
Differential Expression Analysis.
For each of the treated mice, as well as the mock data, we performed differential expression using Seurat's built-in single-cell differential expression tool, with a bimodal distribution model. Differential expression was performed between all pairs of time points available for each dataset. Genes with avg_diff > 1 and pvalue < 0.01 were selected and visualized using the DoHeatmap function in Seurat.
Furthermore, these genes were enriched for upstream regulators using gene set enrichment analysis (GSEA) through the Broad Institute.
Analysis of Primary Tumor Data. Variable genes across primary tumor cells of all mice
were calculated and principal component analysis was performed as described above.
Relevant PCs were determined by visualizing percent variance explained in an elbow plot, significance by Jackstraw (9) , and manual inspection of loadings and coordinates.
Following inspection, PCs 1-5 were selected for downstream visualization of the primary tumor cells by tSNE in Seurat, with perplexity set to 15, and 2500 iterations run.
Assignment of CTCs to Primary Tumor Cluster. Differential expression, as reported
above, was used to identify marker genes that describe the resultant clusters in the primary tumor. These marker genes were used to develop a signature score for each cluster for each of the 96-hr CTCs, using weighted averaging of the genes for each signature (Table S2 ).
Next, we permuted random sets of genes with similarly binned expression distribution and size to create cluster-independent background scores for each CTC. CTCs with clusterspecific signatures above their cluster-independent background were "assigned" to that cluster. CTCs were assigned to all clusters which were above backgroundif a CTC scored above background for more than one cluster, it was assigned to all those clusters; if a CTC scored above background for no clusters, it was classified as "unassigned" (Fig. S13) . The total number of CTCs per mouse for each cluster was visualized by a stacked bar plot, generated through ggplot2 in R. Distributions of assignment between 96-hr CTCs and primary tumors from mice were tested by Fisher's Exact Test, with a cutoff for statistically significant difference set at p<0.05. Table S1 ). The majority of these gene set enrichments are unique to each pair of mouse and time point. Right: Venn diagram shows overlap of differentially expressed genes across all treated mice. . S9 and S10). Rows represent genes, columns represent cells. Time points sampled are provided on the x-axis and selected gene set enrichments for each differentially expressed gene module (identified by hierarchical clustering; see Materials and Methods) are displayed to the left of the relevant cluster (for a full list of enrichments, see Table S2 ). The majority of these gene set enrichments are unique to each pair of mouse and time point.
Supplementary Figures
Fig. S13
. Schematic representation of scoring algorithm used to assign CTCs above background to specific clusters of phenotypes from primary tumor data. CTC signatures were calculated for each cluster of primary tumor cells in Fig. S13A (black dots) and compared to a background generated by permuting random sets of genes with similar mean bins of expression (gray background). CTCs were scored to clusters above background (e.g. top left) or not scored if no clusters were above background (e.g. top middle). (See Materials and Methods for full description of assignment framework).
Fig. S14
. Assignments for 96-hr CTCs and primary tumors based on clusters identified by scRNA-Seq of primary treated and untreated mice. CTCs were assigned (or not assigned) to clusters based on the highest signature score above permuted background (Materials and Methods; Fig. S13) , and the results were visualized using stacked bar plots. UA: unassigned. Similarity tested by Fisher's Exact test (p = 0.99, 0.08, 0.16, and 0.66 for treated mice 1 through 3 and untreated mouse #1, respectively. ✳ = p < 0.05 for untreated mouse # 2). N=18, 8, 7, 52, and 7 CTCs for treated mice 1 through 3 and untreated mice 1 and 2, respectively. N=82, 82, 79, 84, and 75 primary tumor cells for treated mice 1 through 3 and untreated mice 1 and 2, respectively. 
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